Literature DB >> 19771242

Lapatinib - overview and current role in metastatic breast cancer.

Arlene Chan1.   

Abstract

Entities:  

Year:  2006        PMID： 19771242      PMCID： PMC2741644          DOI： 10.4143/crt.2006.38.4.198

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN： 1598-2998            Impact factor:   4.679


× No keyword cloud information.
  6 in total

Review 1.  Targeting the epidermal growth factor receptor for cancer therapy.

Authors:  John Mendelsohn
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

2.  Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.

Authors:  Howard A Burris; Herbert I Hurwitz; E Claire Dees; Afshin Dowlati; Kimberly L Blackwell; Bert O'Neil; Paul K Marcom; Matthew J Ellis; Beth Overmoyer; Suzanne F Jones; Jennifer L Harris; Deborah A Smith; Kevin M Koch; Andrew Stead; Steve Mangum; Neil L Spector
Journal:  J Clin Oncol       Date:  2005-06-13       Impact factor: 44.544

3.  Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.

Authors:  Neil L Spector; Wenle Xia; Howard Burris; Herbert Hurwitz; E Claire Dees; Afshin Dowlati; Bert O'Neil; Beth Overmoyer; Paul K Marcom; Kimberly L Blackwell; Deborah A Smith; Kevin M Koch; Andrew Stead; Steven Mangum; Matthew J Ellis; Leihua Liu; Albert K Man; Troy M Bremer; Jennifer Harris; Sarah Bacus
Journal:  J Clin Oncol       Date:  2005-01-31       Impact factor: 44.544

4.  Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

Authors:  Gottfried E Konecny; Mark D Pegram; Natarajan Venkatesan; Richard Finn; Guorong Yang; Martina Rahmeh; Michael Untch; David W Rusnak; Glenn Spehar; Robert J Mullin; Barry R Keith; Tona M Gilmer; Mark Berger; Karl C Podratz; Dennis J Slamon
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

5.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

Review 6.  HER-2-targeted therapy: lessons learned and future directions.

Authors:  Rita Nahta; Francisco J Esteva
Journal:  Clin Cancer Res       Date:  2003-11-01       Impact factor: 12.531
  6 in total
  2 in total

1.  Circular RNA circ-MMP11 Contributes to Lapatinib Resistance of Breast Cancer Cells by Regulating the miR-153-3p/ANLN Axis.

Authors:  Xiaoli Wu; Yi Ren; Rong Yao; Leilei Zhou; Ruihua Fan
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

2.  Activated estrogen receptor-mitogen-activated protein kinases cross talk confer acquired resistance to lapatinib.

Authors:  Zhe Li; Sheng-Sheng Yang; Pei-Hao Yin; Tao Chang; Lin-Xiang Shi; Lin Fang; Guo-En Fang
Journal:  Thorac Cancer       Date:  2015-02-13       Impact factor: 3.500
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.